| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.03 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |